Pfizer (PFE) has resolved the legal challenge filed by advocacy group Do No Harm to the company's Breakthrough fellowship program, with a New York district court dismissing the case Friday.
According to the court document, Pfizer changed the criteria for the program in February 2023 and has announced that it will no longer accept new applications after the program's fifth and final cohort of fellows.
Do No Harm filed the lawsuit in September 2022, claiming that the program was "racially discriminatory."
Pfizer did not immediately respond to MT Newswires' request for comment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.